InterMune says HCV protease inhibitor shows strong potency, drug resistance

By Elaine Rigoli

Tampa, Fla., May 23 - InterMune, Inc. released data describing the preclinical characterization of ITMN-191 (previously referred to as ITMN B), its orally available hepatitis C virus (HCV) NS3/4A protease inhibitor.

InterMune said ITMN-191 retains activity against variants that exhibit reduced sensitivity to other experimental HCV protease inhibitors in development.

A single variant was identified that shows diminished potency to ITMN-191, according to a news release.

However, this variant is distinct from variants that have reduced sensitivity to other HCV protease inhibitors, the release said.

This demonstrates a favorable cross-resistance profile of ITMN-191 with other HCV protease inhibitors currently in development.

InterMune said it expects to submit a European Clinical Trial Authorization for ITMN-191 in the third quarter of 2006.

Based in Brisbane, Calif., InterMune is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and hepatology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.